Nasus Pharma (NSRX) Cash from Operations (2024)

Nasus Pharma (NSRX) reported Cash from Operations of 180000.0 for Q4 2024.

Nasus Pharma (NSRX) Cash from Operations (2024) Analysis & Trends

Nasus Pharma has reported Cash from Operations for 1 years, with the latest figure at 180000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Ops. (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	1.82 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	5.33 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	2.51 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	3.83 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	3.92 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	2.19 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	2.54 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	2.62 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	1.10 Bn
10	Nasus Pharma	24.83 Mn	20.55 Mn	-	-

Download Data

Date	Value
Dec 31, 2024	-180,000.00
Dec 31, 2024	-180,000.00